Cellectar BioSciences posts corporate presentation on iopofosine I-131 path toward accelerated approval in Waldenstrom macroglobulinemia

• Cellectar highlighted Phase 2b CLOVER-WaM data for iopofosine I 131 in relapsed/refractory Waldenström macroglobulinemia, meeting the primary endpoint.
• Updated CLOVER-WaM efficacy showed ORR 83.6% and MRR 61.8% in the evaluable population; median duration of response 17.8 months.
• Median progression-free survival was 13.5 months; earlier-line patients showed longer median duration of response at 21.2 months.
• Regulatory strategy centered on a U.S. accelerated approval filing using CLOVER-WaM data; potential approval targeted for 2027.
• Phase 3 confirmatory study planned in post-BTK inhibitor patients, 200 total enrollment; estimated total study cost USD 42 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.